Electroencephalography Is a Good Complement to Currently Established Dementia Biomarkers

Dementia and Geriatric Cognitive Disorders

Volumn 42, Issue 1-2, 2016, Pages 80-92

  Ferreira, Daniel ^a   Jelic, Vesna ^a   Cavallin, Lena ^b,c   Oeksengaard, Anne Rita ^a   Snaedal, Jon ^d   Høgh, Peter ^e   Andersen, Birgitte Bo ^f   Naik, Mala ^g   Engedal, Knut ^h   Westman, Eric ^a   Wahlund, Lars Olof ^a  

^a Department of Neurobiology   (Sweden)

^b Division of Medical Imaging and Technology   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Mental Health Center Glostrup   (Denmark)

^g Deaconess Hospital   (Norway)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Alzheimer's disease; Cognition; Diagnosis; Differential diagnosis; Disease biomarkers; Electroencephalography; Statistical pattern recognition; Visual rating scale

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; ELECTROENCEPHALOGRAPH; ELECTROENCEPHALOGRAPHY; FEMALE; FRONTAL CORTEX; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATTERN RECOGNITION; PRIORITY JOURNAL; TEMPORAL CORTEX; ATROPHY; BRAIN CORTEX; CLINICAL TRIAL; DEMENTIA ASSESSMENT; DIAGNOSTIC IMAGING; PATHOLOGY; PROCEDURES; PSYCHOLOGY; REPRODUCIBILITY; STANDARDS; SWEDEN;

BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ATROPHY; BIOMARKERS; CEREBRAL CORTEX; DIAGNOSIS, DIFFERENTIAL; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MENTAL STATUS AND DEMENTIA TESTS; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS; SWEDEN;

EID: 84986588472     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000448394     Document Type: Article

References (56)

1. Dubois B, Feldman HH, Jacova C, et al: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.
2. Dubois B, Feldman HH, Jacova C, et al: Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127.
3. Dubois B, Feldman HH, Jacova C, et al: Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-629.
4. McKhann GM, Knopman DS, Chertkow H, et al: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269.
5. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
6. Oksengard AR, Cavallin L, Axelsson R, et al: Lack of accuracy for the proposed 'Dubois criteria' in Alzheimer's disease: a validation study from the Swedish Brain Power initiative. Dement Geriatr Cogn Disord 2010; 30: 374-380.
7. Ferreira D, Perestelo-Pérez L, Westman E, Wahlund LO, Sarriá A, Serrano-Aguilar P: Meta-review of CSF core biomarkers in Alzheimer's disease: the state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci 2014; 6: 47.
8. Jelic V, Kowalski J: Evidence-based evaluation of diagnostic accuracy of resting EEG in dementia and mild cognitive impairment. Clin EEG Neurosci 2009; 40: 129-142.
9. Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M: EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 2008; 131: 690-705.
10. De Haan W, Pijnenburg YA, Strijers RL, et al: Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. BMC Neurosci 2009; 10: 101.
11. Gawel M, Zalewska E, Szmidt-Sakowska E, Kowalski J: The value of quantitative EEG in differential diagnosis of Alzheimer's disease and subcortical vascular dementia. J Neurol Sci 2009; 283: 127-133.
12. Johnsen K, Johannesson G, Emilsdottir Á, Helgadóttir H, Blin N, Newmann P: MentisCura Diagnostic Tool for Dementia. 2009. www. mentiscura. com.
13. Snaedal J, Johannesson GH, Gudmundsson TE, Gudmundsson S, Pajdak TH, Johnsen K: The use of EEG in Alzheimer's disease, with and without scopolamine-a pilot study. Clin Neurophysiol 2010; 121: 836-841.
14. Snaedal J, Johannesson GH, Gudmundsson TE, et al: Diagnostic accuracy of statistical pattern recognition of electroencephalogram registration in evaluation of cognitive impairment and dementia. Dement Geriatr Cogn Disord 2012; 34: 51-60.
15. Engedal K, Snaedal J, Hoegh P, et al: Quantitative EEG applying the statistical recognition pattern method: a useful tool in dementia diagnostic workup. Dement Geriatr Cogn Disord 2015; 40: 1-12.
16. Ommundsen N, Engedal K, Ksengård AR: Validity of the quantitative EEG statistical pattern recognition method in diagnosing Alzheimer's disease. Dement Geriatr Cogn Disord 2011; 31: 195-201.
17. Johannsson M, Snaedal J, Johannesson GH, Gudmundsson TE, Johnsen K: The acetylcholine index: an electroencephalographic marker of cholinergic activity in the living human brain applied to Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 2015; 39: 132-142.
18. Román G, Tatemichi T, Erkinjuntti T, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-260.
19. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
20. Neary D, Snowden J, Gustafson L, et al: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554.
21. Winblad B, Palmer K, Kivipelto M, et al: Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256: 240-246.
22. Jessen F, Amariglio RE, van Boxtel M, et al: A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 2014; 10: 844-852.
23. Wattjes MP, Henneman WJP, van der Flier WM, et al: Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. Radiology 2009; 253: 174-183.
24. Scheltens P, Leys D, Barkhof F, et al: Atrophy of medial temporal lobes on MRI in 'probable' Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967-972.
25. Ferreira D, Cavallin L, Granberg T, et al: Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. Eur Radiol 2016; 26: 2597-2610.
26. Koedam EL, Lehmann M, van der Flier WM, et al: Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011; 21: 2618-2625.
27. Ferreira D, Cavallin L, Larsson EM, et al: Practical cut-offs for visual rating scales of medial temporal, frontal, and posterior atrophy in Alzheimer's disease and mild cognitive impairment. J Intern Med 2015; 278: 277-290.
28. Pereira JB, Cavallin L, Spulber G, et al: Influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs. J Intern Med 2014; 275: 317-330.
29. Westman E, Cavallin L, Muehlboeck JS, et al: Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. PLoS One 2011; 6:e22506.
30. Cavallin L, Bronge L, Zhang Y, et al: Comparison between visual assessment of MTA and hippocampal volumes in an elderly, non-demented population. Acta Radiol 2012; 53: 573-579.
31. Garcia-Ptacek S, Cavallin L, Kåreholt I, et al: Subjective cognitive impairment subjects in our clinical practice. Dement Geriatr Cogn Dis Extra 2014; 4: 419-430.
32. Enache D, Cavallin L, Lindberg O, et al: Medial temporal lobe atrophy and depressive symptoms in elderly patients with and without Alzheimer disease. J Geriatr Psychiatry Neurol 2015; 28: 40-48.
33. Cavallin L, Løken K, Engedal K, et al: Overtime reliability of medial temporal lobe atrophy rating in a clinical setting. Acta Radiol 2012; 53: 318-323.
34. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
35. Engedal K, Haugen P, Gilje K, Laake P: Efficacy of short mental tests in the detection of mental impairment in old age. Compr Gerontol A 1988; 2: 87-93.
36. Morris J, Heyman A, Mohs R, et al: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39: 1159-1165.
37. Consensus report of the Working Group on: 'Molecular and Biochemical Markers of Alzheimer's Disease'. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working GROUP. Neurobiol Aging 1998; 19: 109-116.
38. Kowalski JW, Gawel M, Pfeffer A, Barcikowska M: The diagnostic value of EEG in Alzheimer disease: correlation with the severity of mental impairment. J Clin Neurophysiol 2001; 18: 570-575.
39. Jeong J: EEG dynamics in patients with Alzheimer's disease. Clin Neurophysiol 2004; 115: 1490-1505.
40. Harper L, Fumagalli GG, Barkhof F, et al: MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain 2016; 139: 1211-1225.
41. Mollenhauer B, Förstl H, Deuschl G, Storch A, Oertel W, Trenkwalder C: Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. Dtsch Arztebl Int 2010; 107: 684-691.
42. Barkhof F, Polvikoski TM, van Straaten ECW, et al: The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 2007; 69: 1521-1527.
43. Schoonenboom NSM, van der Flier WM, Blankenstein MA, et al: CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. Neurobiol Aging 2008; 29: 669-675.
44. Duara R, Loewenstein DA, Shen Q, et al: The utility of age-specific cut-offs for visual rating of medial temporal atrophy in classifying Alzheimer's disease, MCI and cognitively normal elderly subjects. Front Aging Neurosci 2013; 5: 47.
45. O'Donovan J, Watson R, Colloby SJ, et al: Does posterior cortical atrophy on MRI discriminate between Alzheimer's disease, dementia with Lewy bodies, and normal aging Int Psychogeriatr 2013; 25: 111-119.
46. Lehmann M, Koedam EL, Barnes J, et al: Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiol Aging 2012; 33: 627. e1-627. e12.
47. Hsu YY, Du AT, Schuff N, Weiner MW: Magnetic resonance imaging and magnetic resonance spectroscopy in dementias. J Geriatr Psychiatry Neurol 2001; 14: 145-166.
48. Busse A, Hensel A, Gühne U, Angermeyer MC, Riedel-Heller SG: Mild cognitive impairment: long-term course of four clinical subtypes. Neurology 2006; 67: 2176-2185.
49. Orellana C, Ferreira D, Muehlboeck JS, et al: Measuring global brain atrophy with the brain volume/cerebrospinal fluid index: normative values, cut-offs and clinical associations. Neurodegener Dis 2016; 16: 77-86.
50. Kramberger MG, Kåreholt I, Andersson T, Winblad B, Eriksdotter M, Jelic V: Association between EEG abnormalities and CSF biomarkers in a memory clinic cohort. Dement Geriatr Cogn Disord 2013; 36: 319-328.
51. Eriksdotter-Jönhagen M, Linderoth B, Lind G, et al: Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2012; 33: 18-28.
52. Lehtovirta M, Partanen J, Könönen M, et al: A Longitudinal quantitative EEG study of Alzheimer's disease: relation to apolipoprotein E polymorphism. Dement Geriatr Cogn Disord 2000; 11: 29-35.
53. Karami A, Eyjolfsdottir H, Vijayaraghavan S, et al: Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. Alzheimers Dement 2015; 11: 1316-1328.
54. Eyjolfsdottir H, Eriksdotter M, Linderoth B, et al: Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device. Alzheimers Res Ther 2016; 8: 30.
55. Rivero-Santana A, Ferreira D, Perestelo-Pérez L, et al: CSF biomarkers for the differential diagnosis between Alzheimer's disease and frontotemporal lobar degeneration: systematic review, HSROC analysis and confounding factors. J Alzheimers Dis 2016, in press.
56. Morris JC, Blennow K, Froelich L, et al: Harmonized diagnostic criteria for Alzheimer's disease: recommendations. J Intern Med 2014; 275: 204-213.